COMMUNIQUÉS West-GlobeNewswire

Autonomix Announces Reverse Stock Split

22/10/2024 - 14:30

THE WOODLANDS, TX, Oct. 22, 2024 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company focused on advancing precision nerve-targeted treatments, today [...]

SeaStar Medical to Distribute QUELIMMUNE Directly to Hospital Customers

22/10/2024 - 14:30

DENVER, Oct. 22, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage medical device company developing proprietary solutions to reduce the consequences of hyperinflammation on [...]

HealthLynked Announces Strategic Partnership with 3X4 Genetics to Enhance Member Offerings

22/10/2024 - 14:30

NAPLES, Fla., Oct. 22, 2024 (GLOBE NEWSWIRE) -- -- via IBN -- HealthLynked Corp. ( OTCQB: HLYK ), a leading global healthcare network focused on improving healthcare access and outcomes through data-driven solutions, [...]

Celularity Provides Corporate Update

22/10/2024 - 14:30

FLORHAM PARK, N.J., Oct. 22, 2024 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity”), a regenerative and cellular medicine company, has issued a Corporate Update to Shareholders from Robert J. Hariri, M.D [...]

Florida Oncology and Hematology and American Oncology Network Opens New Location in Cape Coral, Welcomes Medical Director, Dr. Van den Bergh, and Drs. Venkata Parsa, and Shivtaj Mann

22/10/2024 - 14:05

Board-certified medical oncologists Magali Van den Bergh, MD, Venkata Parsa, MD, and Shivtaj Mann, DO join the Cape Coral physician team CAPE CORAL, FL.,, Oct. 22, 2024 (GLOBE NEWSWIRE) -- Community oncology practice [...]

Catalyst Pharmaceuticals to Report Third Quarter 2024 Financial Results on November 6, 2024

22/10/2024 - 14:03

The Company will Host a Conference Call and Webcast on Thursday, November 7, 2024, at 8:30 AM ET CORAL GABLES, Fla., Oct. 22, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: [...]

Allarity Therapeutics to be Granted European Patent for DRP® Companion Diagnostic for Stenoparib

22/10/2024 - 14:00

European Patent Office to grant a patent for DRP ® companion diagnostic for Allarity’s stenoparib cancer therapy Patent applications for the Stenoparib DRP ® are also pending in the US, Japan, China, Australia, and [...]

Reflect Scientific Inc. Secures $225,000 Order for Cutting-Edge Freezer Systems

22/10/2024 - 14:00

OREM, Utah, Oct. 22, 2024 (GLOBE NEWSWIRE) -- Reflect Scientific Inc. (OTCQB: RSCF), a leading innovator in cryogenic technology, announced today that it has received a $225,000 order for its state-of-the-art blast [...]

Taysha Gene Therapies to Present Biodistribution Data from an Analysis Evaluating AAV9 Gene Therapy Delivery at the Upcoming 31st Annual ESGCT Congress

22/10/2024 - 14:00

Data from an analysis of five NHP studies showed lumbar IT administration led to widespread and consistent biodistribution of AAV9 gene therapy vectors across brain and spinal cord regions IT and ICM administration [...]

Monopar Presents Encouraging Human Clinical Dosimetry Data on its uPAR Program at EANM 2024

22/10/2024 - 14:00

WILMETTE, Ill., Oct. 22, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage radiopharmaceutical company focused on developing innovative treatments for cancer patients, is presenting [...]

XOMA Royalty Significantly Expands its Royalty and Milestone Portfolio with the Addition of Over 60 Early-Stage Programs from Twist Bioscience

22/10/2024 - 14:00

XOMA Royalty has acquired 50 percent of Twist’s existing royalty and milestone economics for $15 million XOMA Royalty’s portfolio now holds over 100 assets ranging from revenue-generating commercial therapeutics to pre- [...]

Recursion announces first patient dosed in Phase 2 clinical study of REC-3964, a potential first-in-class, oral, non-antibiotic small molecule for recurrent Clostridioides difficile infection

22/10/2024 - 14:00

REC-3964 is Recursion’s first new chemical entity developed using the RecursionOS. REC-3964 represents a novel, non-antibiotic approach with a unique mechanism of action that binds and blocks catalytic activity of the [...]

Annovis to Highlight Buntanetap's Alzheimer's Research Progress with Presentations at CTAD 2024

22/10/2024 - 14:00

MALVERN, Pa., Oct. 22, 2024 (GLOBE NEWSWIRE) -- via IBN – Annovis Bio Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a late-stage clinical drug platform company developing transformative therapies for neurodegenerative [...]

Mineralys to Host Virtual KOL Event on the Unmet Medical Need in Uncontrolled and Resistant Hypertension, and Lorundrostat as a Potential Treatment on October 30, 2024

22/10/2024 - 14:00

RADNOR, Pa., Oct. 22, 2024 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD [...]

PDS Biotech Announces Presentation of Rationale and Design of First Recurrent Prostate Cancer Trial to Combine an Androgen Receptor Pathway Inhibitor with an Immunocytokine

22/10/2024 - 14:00

Study to evaluate PDS01ADC + Xtandi® (Enzalutamide) versus Xtandi® alone to be presented by Dr. Ravi Madan, National Cancer Institute at Cytokines 2024 PRINCETON, N.J., Oct. 22, 2024 (GLOBE NEWSWIRE) -- PDS [...]

MangoRx Announces Formation of Strategy and Alternatives Committee

22/10/2024 - 14:00

Dallas, Texas, Oct. 22, 2024 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX) (“MangoRx” or the “Company”), a company focused on developing, marketing, and selling men’s health and wellness products via a secure [...]

Grifols Partners with BARDA for Proof-of-Concept Testing of Ocular Immunoglobulin as Treatment for Sulfur Mustard-Induced Eye Injury

22/10/2024 - 14:00

Initiative will test Grifols ocular surface immunoglobulin (OSIG) eye drops to evaluate their nonclinical efficacy in neutralizing symptoms from exposure to sulfur mustard, a chemical warfare agent A successful [...]

Indaptus Therapeutics Announces Clinical Supply Agreement with BeiGene to Evaluate Novel Cancer Treatment Combinations

22/10/2024 - 14:00

Planned industry first clinical trial combining BeiGene's checkpoint inhibitor tislelizumab with Indaptus’ broadly targeted, short duration systemic immune stimulator Decoy20 expected to start in 2025 Indaptus [...]

Aligos Therapeutics Announces U.S. FDA Clearance of IND Application for ALG-000184

22/10/2024 - 14:00

Company to conduct a Phase 1 Drug-Drug Interaction Study Phase 2 filing on track for Q1 2025 SOUTH SAN FRANCISCO, Calif., Oct. 22, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical [...]